MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.48
+0.03
+0.55%
After Hours: 5.48 0 0.00% 16:31 09/17 EDT
OPEN
5.49
PREV CLOSE
5.45
HIGH
5.66
LOW
5.34
VOLUME
3.20M
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
3.360
MARKET CAP
1.13B
P/E (TTM)
-13.7896
1D
5D
1M
3M
1Y
5Y
Precigen Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Precigen's (NASDAQ:PGEN) reported sales totaled $33.58 million. Despite a 11.39% increase in earnings, the company posted a loss of $15.67 million.
Benzinga · 20h ago
Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in two ...
PR Newswire · 09/01 12:05
Polygon Management Ltd. Buys Takeda Pharmaceutical Co, Ping Identity Holding Corp, KKR ...
GuruFocus News · 08/18 19:38
Insider Trends: 90-Day Insider Selling Trend Prolonged at Precigen
MT Newswires · 08/17 18:05
Insider Trends: Selling By Insiders Lingers at Precigen
MT Newswires · 08/13 18:17
Insider Trends: Insider Adds to Selling Trend at Precigen
MT Newswires · 08/11 18:06
Precigen, Inc. (PGEN) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/09 21:35
Precigen: Q2 Earnings Insights
Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 61.54% year over year to ($0.10), which beat the estimate of ($0.12).
Benzinga · 08/09 20:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PGEN stock price target is 13.80 with a high estimate of 17.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 246
Institutional Holdings: 144.43M
% Owned: 69.89%
Shares Outstanding: 206.64M
TypeInstitutionsShares
Increased
57
4.64M
New
12
652.88K
Decreased
35
3.28M
Sold Out
27
1.97M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
Declaration Date
Dividend Per Share
Ex-Div Date
06/08/2015
Dividend USD 0.162
06/09/2015
  • All
  • Financials
  • Insiders
More
About PGEN
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.